Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML

GlobeNewswire March 24, 2016

Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062

GlobeNewswire March 23, 2016

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights

GlobeNewswire March 10, 2016

Sunesis to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights

GlobeNewswire March 3, 2016

Sunesis Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference

GlobeNewswire March 1, 2016

Sunesis Pharmaceuticals Announces Promotion of Deborah A. Thomas, Ph.D., to Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development

GlobeNewswire February 19, 2016

Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML

GlobeNewswire January 4, 2016

Sunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriter's Over-Allotment Option

GlobeNewswire December 21, 2015

Sunesis Announces Pricing of $25 Million Offering of Securities

GlobeNewswire December 16, 2015

Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe

GlobeNewswire December 8, 2015

Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial in AML at ASH Annual Meeting

GlobeNewswire December 7, 2015

Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase 1/2 Trial of Vosaroxin in MDS and VALOR Analysis of Baseline Safety Predictors at ASH Annual Meeting

GlobeNewswire December 6, 2015

Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire December 3, 2015

Sunesis Pharmaceuticals Announces First Patient Treated in Indiana University Pilot Study of Vosaroxin and Cytarabine in Adults Age 60 Years and Older With Previously Untreated AML

GlobeNewswire December 1, 2015

Sunesis Pharmaceuticals Announces European Patent Covering Vosaroxin Combination Use in AML and Other Hematologic Malignancies

GlobeNewswire November 30, 2015

Sunesis Pharmaceuticals Presents Preclinical Data From Its BTK and PDK1 Inhibitor Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire November 9, 2015

Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting

GlobeNewswire November 5, 2015

Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights

GlobeNewswire November 5, 2015

Sunesis Pharmaceuticals Announces Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at the 2015 Chemotherapy Foundation Symposium

GlobeNewswire November 4, 2015

Sunesis to Host Conference Call on November 5th to Discuss Third Quarter 2015 Financial Results and Recent Highlights

GlobeNewswire October 29, 2015